Rhino Biotech Limited (RBRXF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.99 Thousand | -20.66 Thousand | -17.15 Thousand | -17.43 Thousand | -22.98 | -30.20 |
| Net Income | -21.23 Thousand | -20.42 Thousand | -13.87 Thousand | -22.83 Thousand | -24.40 | -29.50 |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 5237.00 | -244.00 | -3283.00 | 5403.00 | 1.19 | -0.32 |
| Other non-cash items | - | 1589.00 | -4.22 | -5403.00 | 0.22 | -0.37 |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 15.87 Thousand | 20.32 Thousand | 15 Thousand | - | - | - |
| Debt repayment | -15.87 | -20.32 Thousand | -15 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 15.87 Thousand | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | -1833.00 | - | 5403.00 | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 5237.00 | -244.00 | -3283.00 | - | 1.19 | -0.32 |
| Cash at beginning of period | 1518.00 | 1865.00 | 4020.00 | 21.45 Thousand | 44.44 | 74.63 |
| Cash at end of period | 1393.00 | 1518.00 | 1865.00 | 4020.00 | 21.45 | 44.44 |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -125.00 | -347.00 | -2155.00 | -17.43 Thousand | -22.98 | -30.20 |
| Free Cash Flow | -15.99 Thousand | -20.66 Thousand | -17.15 Thousand | -17.43 Thousand | -22.98 | -30.20 |
| Breakdown | 2020 FY | 2019 FY | 2018 FY | 2017 FY | 2016 FY | 2015 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -21.23 Thousand | -20.42 Thousand | -13.87 Thousand | -22.83 Thousand | -24.40 | -29.50 |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 5237.00 | -244.00 | -3283.00 | 5403.00 | 1.19 | -0.32 |
| Other non-cash items | - | 1589.00 | -4.22 | -5403.00 | 0.22 | -0.37 |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 15.87 Thousand | 20.32 Thousand | 15 Thousand | - | - | - |
| Debt repayment | -15.87 | -20.32 Thousand | -15 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 15.87 Thousand | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | -1833.00 | - | 5403.00 | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 5237.00 | -244.00 | -3283.00 | - | 1.19 | -0.32 |
| Cash at beginning of period | 1518.00 | 1865.00 | 4020.00 | 21.45 Thousand | 44.44 | 74.63 |
| Cash at end of period | 1393.00 | 1518.00 | 1865.00 | 4020.00 | 21.45 | 44.44 |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -125.00 | -347.00 | -2155.00 | -17.43 Thousand | -22.98 | -30.20 |
| Free Cash Flow | -15.99 Thousand | -20.66 Thousand | -17.15 Thousand | -17.43 Thousand | -22.98 | -30.20 |
BAS
DXIEF
NFTFF
HEBA-B
BTDR
048530